Drug Trial Radar · NCT06948981
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
46
Planned (sponsor's estimate)
Start
Apr 18, 2025
Primary completion
Apr 17, 2028
Study completion Apr 17, 2028
Sponsor
- Lead sponsor
- Grit BiotechnologyIndustry
- Sponsor type
- Industry
- Collaborators
- Institute of Hematology & Blood Diseases Hospital, China
- First posted
- Apr 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective single-arm open-labled phase I/II clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 46 subjects (anticipated) will be enrolled in this study.
Conditions
- Hematological Malignancy (Leukemia- Lymphoma)
Interventions
GT719 InjectionBiological
GT719 Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events per CTCAE 5.0Time frame: From infusion to the end of the treatment at 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.